Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Suzhou Highfine Biotech Co FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Suzhou Highfine Biotech Co FCF Yield % Related Terms
Suzhou Highfine Biotech Co FCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Suzhou Highfine Biotech Co's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Suzhou Highfine Biotech Co FCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Suzhou Highfine Biotech Co's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Suzhou Highfine Biotech Co's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Suzhou Highfine Biotech Co (SZSE:301393) has a FCF Yield % of -2.64 as of Aug. 24, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Suzhou Highfine Biotech Co and its competitors. According to the industry distribution chart, Suzhou Highfine Biotech Co ranks #682 out of 1002 companies in the Drug Manufacturers industry, placing it in the top 68.1%.
Is Suzhou Highfine Biotech Co's FCF Yield % too high?
Suzhou Highfine Biotech Co's current FCF Yield % is -2.64. Based on the distribution chart, Suzhou Highfine Biotech Co ranks #682 out of 1002 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Suzhou Highfine Biotech Co has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Suzhou Highfine Biotech Co's FCF Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Suzhou Highfine Biotech Co ranks #682 out of 1002 companies for FCF Yield %. This places Suzhou Highfine Biotech Co in the lower half of its industry. The industry median FCF Yield % is 0.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.69, based on 1,002 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Suzhou Highfine Biotech Co and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Suzhou Highfine Biotech Co's current FCF Yield % is -2.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Suzhou Highfine Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Suzhou Highfine Biotech Co (SZSE:301393) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥71.95, compared to a current price of ¥61.32 — trading 14.8% below its estimated fair value. The current FCF Yield % is -2.64. Suzhou Highfine Biotech Co's overall GF Score™ is 91/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Suzhou Highfine Biotech Co (SZSE:301393), the current FCF Yield % is -2.64 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Suzhou Highfine Biotech Co (SZSE:301393) Overvalued in 2026?
Based on GuruFocus' analysis, Suzhou Highfine Biotech Co stock appears to be undervalued.
The current stock price of ¥61.32 is trading 14.8% below its estimated GF Value™ of ¥71.95.
GuruFocus considers Suzhou Highfine Biotech Co to be Modestly Undervalued.
Key valuation signals for SZSE:301393:
FCF Yield %: -2.64
GF Value™: ¥71.95 vs. price of ¥61.32 (14.8% below fair value)
No single metric tells the full story. See the SZSE:301393 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Suzhou Highfine Biotech Co Ltd is a high-tech enterprise that provides characteristic raw materials for global pharmaceutical research and development and raw material drug production companies. The products are mainly used in the fields of peptide, nucleotide and pharmaceutical synthesis. The product range covers peptide synthesis reagents for characteristic amide bond formation, molecular building blocks, protein reagents, liposome and lipid nanoparticle pharmaceutical reagents, ionic liquids , PROTAC reagents and nucleotide reagents and other types.
91GF Score
Get the complete analysis for SZSE:301393
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:301393 has been successfully added to your 
